Haemonetics Corporation HAE
NYSE
| 09/26/2026 | 06/27/2026 | 03/28/2026 | 12/27/2025 | 09/27/2025 | |
|---|---|---|---|---|---|
| Net Income | 40.28% | 263.85% | -145.03% | 15.66% | 13.67% |
| Total Depreciation and Amortization | 2.39% | 27.77% | -22.52% | -3.08% | -1.75% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 30.72% | -82.52% | 625.21% | -47.36% | 81.33% |
| Change in Net Operating Assets | 290.36% | -229.61% | -151.39% | -54.74% | 147.02% |
| Cash from Operations | 144.83% | -26.24% | -24.18% | -15.95% | 539.96% |
| Capital Expenditure | -86.83% | 55.23% | -178.17% | -26.57% | -33.62% |
| Sale of Property, Plant, and Equipment | 143.04% | -54.94% | 21.76% | 260.00% | -59.60% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 30.71% | -56.65% | 60.52% | 7.91% | 13.44% |
| Cash from Investing | -9.23% | 74.33% | -193.94% | 3.29% | 7.67% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | 82.90% | -19,193.79% | -0.06% | 0.06% |
| Issuance of Common Stock | -45.03% | 2,809.02% | -96.76% | 5,884.13% | -98.40% |
| Repurchase of Common Stock | 88.91% | 96.50% | -62,428.75% | 99.79% | -1,469.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -125,700.00% | -7.69% | 7.14% | 64.10% | -8.33% |
| Cash from Financing | -31.21% | 49.23% | -5,092.57% | 102.66% | -3,034.81% |
| Foreign Exchange rate Adjustments | 282.50% | 18.39% | -193.33% | 204.79% | -118.48% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 269.24% | 81.30% | -276.17% | 1,797.42% | 125.45% |